Marquette Asset Management Exits Position in Aduro BioTech Inc (ADRO)

Aduro BioTech Inc (ADRO) : Marquette Asset Management has sold out all of its stake in Aduro BioTech Inc during the most recent quarter, according to the disclosure filed by the company on Apr 13, 2016 with the SEC. The investment management company has sold out 350,000 shares of Aduro BioTech Inc which is valued at $4,810,750.

Aduro BioTech Inc opened for trading at $13.61 and hit $14.19 on the upside on Monday, eventually ending the session at $13.76, with a gain of 0.11% or 0.015 points. The heightened volatility saw the trading volume jump to 2,59,391 shares. Company has a market cap of $888 M.

On the company’s financial health, Aduro BioTech Inc reported $0.04 EPS for the quarter, beating the analyst consensus estimate by $ 0.27 according to the earnings call on Mar 8, 2016. Analyst had a consensus of $-0.23. The company had revenue of $34.40 million for the quarter, compared to analysts expectations of $10.83 million. The company’s revenue was up 247.5% compared to the same quarter last year.

Many Wall Street Analysts have commented on Aduro BioTech Inc. Shares were Downgraded by BofA/Merrill on Mar 15, 2016 to ” Underperform” and Lowered the Price Target to $ 14 from a previous price target of $32 .FBR Capital Initiated Aduro BioTech Inc on Mar 2, 2016 to “Outperform”, Price Target of the shares are set at $30.

Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live attenuated Listeria GVAX and cyclic dinucleotides (CDNs). Aduro’s lead program is an immunotherapy regimen combining Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy. Its pipeline includes CRS-207 ADU-623 ADU-214 ADU-741 CDN and STINGVAX. CRS-207 is based on Aduro’s Listeria platform. ADU-623 is Aduro’s first clinical bivalent Listeria-based immunotherapy. ADU-214 is a bivalent Listeria-based immunotherapy that targets both mesothelin and an EGFR mutation. CDNs are small molecules that signal through STING and induce a potent immune response. STINGVAX is the combination of CDNs and GVAX.

Leave a Reply

Aduro BioTech Inc - Is it time to Sell?

Top Brokerage Firms are advising their investors on Aduro BioTech Inc. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.